A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer

Tumori

Volumn 84, Issue 1, 1998, Pages 87-89

  Thibault, Alain ^a,b   Figg, William D ^a   Bergan, Raymond C ^a   Lush, Richard M ^a   Myers, Charles E ^a,c   Tompkins, Anne ^a   Reed, Eddie ^a   Samid, Dvorit ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; bFGF; Chemotherapy; Malignancy; Tumor biology; Tumor markers

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PROTEIN URINE LEVEL; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; VOMITING;

EID: 0031945210     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400120     Document Type: Article

References (17)

1. Crawford E.D., Eisenberger M.A., McLeod D.G., Spaulding J.T., Benson R., Dorr F.A., Blumenstein B.A., Davis M.A., Goodman P.J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Eng. J. Med., 321: 419-24, 1989.
2. Eisenberger M.A.: Chemotherapy for prostate carcinoma. NCI Monogr. 7: 151-63, 1988.
3. Folkman J.: The role of angiogenesis in tumor growth. Semin. Cancer Biol., 3: 65-71, 1992.
4. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M.: Silencing of the VHL tumor-suppressor gene by DNA methylation. Cell, 20: 85-90, 1985.
5. Jones P.A., Taylor S.M.: Cellular differentiation, cytidine analogs and DNA methylation in renal carcinoma. Proc Natl. Acad. Scie., 91:9700-4, 1994.
6. Momparler R.L.: Pharmacology of 5-aza-2'-deoxycytidine. Antimetab. Biochem. Biol. Med., 57: 33-41, 1979.
7. Nakamoto T., Chang C.S., Li A.K., Chodak G.W.: Basic fibroblast growth factor in human prostate cancer cells. Cancer Res., 52: 571-7, 1992.
8. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., Folkman J.: Elevated levels of the angiogenic peptide, basic fibroblast growth factor, in urine of patients with wide a spectrum of cancers. J. Nat. Cancer Inst., 86: 356-61, 1993.
9. Pliml I., Sorm F: Synthesis of 2'-deoxy-D-ribofuranosyl-5-azacytosine. Coll. Czech. Chem. Commun., 29: 2576, 1964.
10. Prasanna P., Thibault A., Liu L., Weber J., Samid D.: Therapeutic potentials of 5-aza-2'-deoxycytidine on human prostatic cancer cells. Proc. Am. Assoc. Cancer Res., 36: 404, 1995.
11. Richel D.J., Colly L.P., Willemeze F.: The antileukaemic activity of 5-aza-2'-deoxycytidine (AZA-DC) in patients with relapsed leukemia. Bone Marrow Transplant, 4: 64, 1989.
12. Slavin J.: Fibroblast growth factors: at the heart of angiogenesis. Cell Biol. Int., 19: 431-444, 1995.
13. Stern P.H., Hoffman R.M.: Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro, 20: 663-70, 1984.
14. Van Groeningen C.J., Leyva A., O'Brien A.M., Gall H.E., Pinedo H.M.: Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res., 46: 4831-6, 1986.
15. Walls R., Thibault A., Liu L., Wood C., Kozlowski J.M., Figg W.D., Sampson M.L., Elin R.J., Samid D.: The differentiating agent phenylacetate increases prostate specific antigen production by prostate cancer cells. The Prostate, 29: 177-182, 1996.
16. Ware J.L.: Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev., 12: 287-301, 1993.
17. Weber J., Salgaller M., Samid D., Johnson B., Herlyn M., Lassam N., Treisman J., Rosenberg S.A.: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res., 54: 1766-71, 1994.